{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:30:27Z","timestamp":1772757027157,"version":"3.50.1"},"reference-count":55,"publisher":"Wiley","issue":"S358","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":6353,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1990,4]]},"abstract":"<jats:p><jats:bold>Abstract<\/jats:bold> Variability in the outcome of treatment with antipsychotic drugs may be due to differences in compliance and to variations in pharmacokinetics and concentration\u2010response relationships at the receptor level. Among the various chemical classes of neuroleptics, the butyrophenones, the phenothiazines, and the thioxanthenes have similar pharmacokinetics, and show larger inter\u2010individual variations in plasma drug levels after oral than after intramuscular doses. Compared to the \u201cclassical\u201d neuroleptics, the more water\u2010soluble benzamide derivatives have significantly shorter elimination half\u2010lives, and show smaller inter\u2010patient variations in plasma level: dose<\/jats:p>","DOI":"10.1111\/j.1600-0447.1990.tb05283.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T12:10:52Z","timestamp":1187871052000},"page":"37-40","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetics of antipsychotic drugs in man"],"prefix":"10.1111","volume":"82","author":[{"given":"S. G.","family":"Dahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2165\/00003088-198611010-00003","article-title":"Plasma level monitoring of antipsychotic drugs. Clinical utility","volume":"11","author":"DAHLSG","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_1_3_2","first-page":"39","volume-title":"Clinical pharmacology in psychiatry. From molecular studies to clinical reality","author":"L FARDE.","year":"1989"},{"key":"e_1_2_1_4_2","first-page":"174","volume-title":"Progress in drug metabolism, vol 9","author":"RGENSENA J\u00f8","year":"1986"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00607681"},{"key":"e_1_2_1_6_2","first-page":"206","article-title":"Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients","volume":"96","author":"KK MTDHA.","year":"1988","journal-title":"Psychopharmacology"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00007691-198204000-00005","article-title":"Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects","volume":"4","author":"DAHL SG.","year":"1982","journal-title":"Ther Drug Monit"},{"key":"e_1_2_1_8_2","first-page":"149","volume-title":"Clinical pharmacology in psychiatry. Bridging the experimental\u2010therapeutic gap","author":"SG DAHL.","year":"1983"},{"key":"e_1_2_1_9_2","first-page":"89","article-title":"Inhibitory effects of neuroleptics on debrisoquine oxidation in man","volume":"22","author":"SYV\u00c4LAHTI EKG.","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_10_2","first-page":"210","volume-title":"Clinical pharmacology in psychiatry. From molecular studies to clinical reality","author":"J BENITEZ.","year":"1989"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.109"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1987.tb02995.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_1_14_2","first-page":"56","volume-title":"Leponex (clozapine). Prototype of atypical neuroleptics","author":"GRIMM R.","year":"1986"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/BF00172957","article-title":"Determination of clozapine and its N\u2010demethylated metabolite in plasma by use of gas chromatography\u2010mass spectrometry with single ion detection","volume":"95","author":"U BONDESSON.","year":"1988","journal-title":"Psychopharmacology"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01046700"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jps.2600680224","article-title":"analysis of lozapine, amoxapine and their metabolites in serum and urine","volume":"68","author":"TB COOPER.","year":"1979","journal-title":"J Pharm Sci"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431855"},{"key":"e_1_2_1_19_2","first-page":"277","article-title":"Loxapine: a study of bioequivalency and bioavailability","volume":"28","author":"MA KHAN.","year":"1980","journal-title":"CurrTherRes"},{"key":"e_1_2_1_20_2","first-page":"70","volume-title":"Progress in clinical pharmacy III","author":"J BRES.","year":"1981"},{"key":"e_1_2_1_21_2","first-page":"279","article-title":"Absorption, \u00e9limination et m\u00e9tabolisme du tiapride (FLO\u20101347) \u2010 m\u00e9dicament neuroleptique \u2010 chez le rat, le chien et l'homme","volume":"3","author":"STROLIN\u2010BENEDETTIM DONATH A.","year":"1978","journal-title":"Ann Pharm Fr"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558453"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600730826"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00451679"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00174501","article-title":"Remoxipride \u2010 a new potential antipsychotic drug","volume":"95","author":"L FARDE.","year":"1988","journal-title":"Psychopharmacology"},{"issue":"311","key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0447.1984.tb06859.x","article-title":"Relationship between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine.","volume":"69","author":"G ALFREDSSON.","year":"1984","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_27_2","first-page":"459","article-title":"Blood concentration and clinical effect of haloperidol therapy in combination with levomepromazine","volume":"36","author":"HAYASHIO MTYOSHIS.","year":"1982","journal-title":"Folia Psychiatr Neurol Jpn"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.144.6.625"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978234451"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1975.tb01576.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.137.7.819"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.12.1631"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00004714-198504000-00010","article-title":"Effects of carbamazepine on plasma haloperidol levels.","volume":"5","author":"MW JANN.","year":"1985","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.5.650"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00613934"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.10.1290"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.2.231"},{"key":"e_1_2_1_38_2","first-page":"31","article-title":"Effects of antimalarial agents on plasma levels of chlorpromazine and its metabolites in schizophrenic patients","volume":"40","author":"ROA MAKANJUOLA.","year":"1988","journal-title":"Trop GeogrMed"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5798.463"},{"key":"e_1_2_1_40_2","first-page":"11","article-title":"Effets de la levomepromazine sur le metabolisme de \u013e impramine chez \u013e'homme","volume":"11","author":"JR BOISSIER.","year":"1975","journal-title":"Pharmacol Clin"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00613523"},{"key":"e_1_2_1_42_2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00004714-198312000-00011","article-title":"Thioridazine effect on desipramine plasma levels.","volume":"3","author":"J HIRSCHOWITZ.","year":"1983","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.137.10.1232"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198106060-00003"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000117644"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803010-00002"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780150095010"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.24.040184.002045"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422403"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0364-7722(80)90034-X"},{"key":"e_1_2_1_51_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004714-198302000-00003","article-title":"Blood levels of haloperidol in schizophrenic patients.","volume":"3","author":"A SHVARTSBURD.","year":"1983","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00900.x"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198204000-00006"},{"key":"e_1_2_1_54_2","first-page":"31","article-title":"Combination therapy with haloperidol and orphenadrine in schizophrenia","volume":"12","author":"AC ALTAMURA.","year":"1986","journal-title":"Encephale"},{"key":"e_1_2_1_55_2","first-page":"389","article-title":"Influence of the antiparkinsonian drugs on the plasma level of neuroleptics","volume":"12","author":"J GAUTIER.","year":"1977","journal-title":"Biol Psychiatry"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.149.6.726"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1990.tb05283.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1990.tb05283.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T17:54:45Z","timestamp":1697997285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1990.tb05283.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,4]]},"references-count":55,"journal-issue":{"issue":"S358","published-print":{"date-parts":[[1990,4]]}},"alternative-id":["10.1111\/j.1600-0447.1990.tb05283.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1990.tb05283.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,4]]}}}